---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-006011"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:18:20.948655+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tonix Pharmaceuticals appoints Joseph Hand as General Counsel and EVP of Operations

## Summary
- Joseph Hand appointed General Counsel and EVP of Operations, effective May 14, 2025.
- Hand brings over 20 years biopharma experience; served on Celgene's Executive Committee for nearly a decade.
- Played key roles in Celgene's $74B acquisition by BMS and $13.4B divestiture of Otezla to Amgen.
- Appointment comes as Tonix prepares for potential FDA approval of TNX-102 SL for fibromyalgia by August 15, 2025.
- Hand previously served as Chief Administrative Officer at Phathom Pharmaceuticals.

## SEC filing metadata
- accession: 0001999371-25-006011
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125006011/0001999371-25-006011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125006011/tnxp-8k_051425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-006011
- JSON: https://secwatch.observer/filing/0001999371-25-006011.json
- Plain text: https://secwatch.observer/filing/0001999371-25-006011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.